|
Synonyms: hLL1 | IMMU-115
Compound class:
Antibody
Comment: Milatuzumab is a humanized monoclonal antibody targeting CD74, a cell surface molecule which links the innate and adaptive immune responses by regulating the survival of macrophages and B cells. CD74 is also known as the invariant chain of major histocompatibility complex class II and acts as a receptor for macrophage migration inhibitory factor (MIF).
Milatuzumab may also be conjugated with doxorubicin creating the antibody-drug conjugate (ADC) hLL1-DOX (aka IMMU-110) [1]. Peptide sequence information for this antibody is available from its IMGT/mAb-DB link. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| The first-in-class anti-CD74 monoclonal milatuzumab is being developed to treat hematological malignancies. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Chronic lymphocytic leukemia |
Disease Ontology:
DOID:1040 OMIM: 151400 Orphanet: ORPHA67038 |
FDA and EMA orphan drug for CLL and multiple myeloma; in Phase 2 trial. | |
